References
1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with
Pneumonia in China, 2019. The New England journal of medicine.2020;382(8):727-733.
2. World Health Organization (WHO). Pneumonia of unknown cause - China.
01/05/2020;
https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/.
Accessed 04/15/2020.
3. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology
of 2019 novel coronavirus: implications for virus origins and receptor
binding. Lancet (London, England). 2020;395(10224):565-574.
4. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory
syndrome-related coronavirus–The species and its viruses, a statement
of the Coronavirus Study Group. BioRxiv. 2020.
5. WHO Director-General’s remarks at the media briefing on 2019-nCoV on
11 February 2020 [press release]. 02/11/2020.
6. WHO Director-General’s opening remarks at the media briefing on
COVID-19 - 11 March 2020 [press release]. 03/11/2020.
7. Dong E, Du H, Gardner L. An interactive web-based dashboard to track
COVID-19 in real time. The Lancet Infectious diseases. 2020.
8. World Health Organization (WHO). Coronavirus disease 2019
(COVID-19) Situation Report - 120. 05/19/2020.
9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with
a new coronavirus of probable bat origin. Nature.2020;579(7798):270-273.
10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. Lancet (London,
England). 2020;395(10223):497-506.
11. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of
chemosensory dysfunction and Covid-19 in patients presenting with
influenza-like symptoms. International forum of allergy &
rhinology. 2020.
12. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
Wuhan, China. Jama. 2020.
13. Zu ZY, Jiang MD, Xu PP, et al. Coronavirus Disease 2019 (COVID-19):
A Perspective from China. Radiology. 2020:200490.
14. Centers for Disease Control and Prevention (CDC). Interim infection
prevention and control guidance for dental settings during the COVID-19
response. 2020;
https://www.cdc.gov/coronavirus/2019-ncov/hcp/dental-settings.html.
Accessed 04/15/2020.
15. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface
Stability of SARS-CoV-2 as Compared with SARS-CoV-1. The New
England journal of medicine. 2020;382(16):1564-1567.
16. Sabino-Silva R, Jardim ACG, Siqueira WL. Coronavirus COVID-19
impacts to dentistry and potential salivary diagnosis. Clinical
oral investigations. 2020;24(4):1619-1621.
17. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell
Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
Protease Inhibitor. Cell. 2020.
18. Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from
the ongoing Wuhan outbreak and modeling of its spike protein for risk of
human transmission. Science China Life sciences.2020;63(3):457-460.
19. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H.
Tissue distribution of ACE2 protein, the functional receptor for SARS
coronavirus. A first step in understanding SARS pathogenesis. The
Journal of pathology. 2004;203(2):631-637.
20. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data
analysis on the receptor ACE2 expression reveals the potential risk of
different human organs vulnerable to 2019-nCoV infection.Frontiers of medicine. 2020.
21. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of
2019-nCoV on the epithelial cells of oral mucosa. International
journal of oral science. 2020;12(1):8.
22. To KKW, Yip CCY, Lai CYW, et al. Saliva as a diagnostic specimen for
testing respiratory virus by a point-of-care molecular assay: a
diagnostic validity study. Clinical microbiology and infection :
the official publication of the European Society of Clinical
Microbiology and Infectious Diseases. 2019;25(3):372-378.
23. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019
novel coronavirus in saliva. Clinical infectious diseases : an
official publication of the Infectious Diseases Society of America.2020.
24. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in
posterior oropharyngeal saliva samples and serum antibody responses
during infection by SARS-CoV-2: an observational cohort study. The
Lancet Infectious diseases. 2020;20(5):565-574.
25. Williams E, Bond K, Zhang B, Putland M, Williamson DA. Saliva as a
non-invasive specimen for detection of SARS-CoV-2. Journal of
clinical microbiology. 2020.
26. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more
sensitive for SARS-CoV-2 detection in COVID-19 patients than
nasopharyngeal swabs. medRxiv. 2020.
27. U.S. Food & Drug Administration (FDA). Rutgers Clinical Genomics
Laboratory TaqPath SARS-CoV-2 assay accelerated emergency use
authorization (EUA) summary.
https://www.fda.gov/media/136875/download. Accessed 04/14/2020.
28. Harrel SK, Molinari J. Aerosols and splatter in dentistry: a brief
review of the literature and infection control implications.Journal of the American Dental Association (1939).2004;135(4):429-437.
29. Bentley CD, Burkhart NW, Crawford JJ. Evaluating spatter and aerosol
contamination during dental procedures. Journal of the American
Dental Association (1939). 1994;125(5):579-584.
30. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of
2019-nCoV and controls in dental practice. International journal
of oral science. 2020;12(1):9.
31. Occupational Safety and Health Administration (OSHA). Guidance on
preparing workplaces for COVID-19.
https://www.osha.gov/Publications/OSHA3990.pdf. Accessed
04/15/2020.
32. American Dental Association (ADA). ADA interim guidance for
minimizing risk of COVID-19 transmission.
https://www.ada.org/~/media/CPS/Files/COVID/ADA_COVID_Int_Guidance_Treat_Pts.pdf?utm_source=adaorg&utm_medium=covid-statement-200401&utm_content=cv-pm-ebd-interim-response&utm_campaign=covid-19.
Accessed 04/14/2020.
33. American Association of Oral and Maxillofacial Surgeons (AAOMS).
COVID-19 guidance FAQs.
https://www.aaoms.org/practice-resources/covid-19-guidance-faqs.
Accessed 04/15/2020.
34. Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In Vitro
Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash
Against Respiratory and Oral Tract Pathogens. Infectious diseases
and therapy. 2018;7(2):249-259.
35. Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by
means of povidone-iodine, physical conditions, and chemical reagents.The Japanese journal of veterinary research. 2004;52(3):105-112.
36. Maniakas A, Jozaghi Y, Zafereo ME, et al. Head and neck surgical
oncology in the time of a pandemic: Subsite-specific triage guidelines
during the COVID-19 pandemic. Head & neck. 2020.
37. Swennen GRJ, Pottel L, Haers PE. Custom-made 3D-printed face masks
in case of pandemic crisis situations with a lack of commercially
available FFP2/3 masks. International journal of oral and
maxillofacial surgery. 2020.
38. Prusa Research. 3D printed face shields for medics and
professionals. 2020; https://www.prusa3d.com/covid19/. Accessed
04/15/2020.
39. American Medical Association (AMA). COVID-19: A physician practice
guide to reopening. 5/1/2020;
https://www.ama-assn.org/system/files/2020-05/physican-guide-reopening-practices-covid-19.pdf.
40. Centers for Medicare & Medicaid Services (CMS). Re-opening
facilities to provide non-emergent non-COVID-19 healthcare: Phase 1.
4/19/2020;
https://www.cms.gov/files/document/covid-flexibility-reopen-essential-non-covid-services.pdf.